News and Press Releases
Press releases
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closes $419,124 private placement financing by issuing 1,995,829 units at CAD 0.21 each, with warrants exercisable at CAD 0.32 for 5 years. Funds will support Phase II bladder cancer trials, HSV treatment R&D, Rutherrin®...
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Press ReleaseRuvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms...
Ruvidar Demonstrates 7 Year Complete Response
Press ReleaseA BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat...
Ruvidar Effective in the Treatment of Herpes
Press ReleaseRuvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025....
Theralase® Releases 2024 Annual Financial Statements
Press ReleaseTheralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions....
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closed a non-brokered private placement, raising approximately CAD 310,200 by issuing 1,034,002 units at CAD 0.30 each. Proceeds will fund Phase II bladder cancer trials, Rutherrin® development, working capital, and general...
Theralase® Therapy Improves Motor and Non-Motor Function in Parkinson’s Patients
Press ReleaseTheralase®’s Cool Laser Therapy improved motor and non-motor functions in Parkinson’s patients in a triple-blind clinical study, showing enhanced cognition, neurovascular health, and movement, supporting its potential as a...
Theralase® Demonstrates Efficacy of Rutherrin® in Destruction of Non-Hodgkin’s Lymphoma
Press ReleaseTheralase® reported that Rutherrin®, combined with Metformin and radiation, eliminated Non-Hodgkin’s Lymphoma in an animal model. This trimodal therapy showed tumor regression and survival benefits, supporting its promise in treating...
CORRECTING AND REPLACING: Theralase® Demonstrates Effective Treatment of Herpes
Press ReleaseTheralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate....
Theralase® Demonstrates Effective Treatment of Herpes
Press ReleaseTheralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.